EP4367140A4 - Anti-tnfr2-antikörper und verwendungen davon - Google Patents

Anti-tnfr2-antikörper und verwendungen davon

Info

Publication number
EP4367140A4
EP4367140A4 EP22837100.1A EP22837100A EP4367140A4 EP 4367140 A4 EP4367140 A4 EP 4367140A4 EP 22837100 A EP22837100 A EP 22837100A EP 4367140 A4 EP4367140 A4 EP 4367140A4
Authority
EP
European Patent Office
Prior art keywords
tnfr2 antibody
tnfr2
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22837100.1A
Other languages
English (en)
French (fr)
Other versions
EP4367140A1 (de
Inventor
Nicola Arturo Aldo BELTRAMINELLI
Jennifer Watkins
Francisco Adrian
Qian Zhang
Andreas Raue
Pascaline Mary
Liang SCHWEIZER
Shuo WEI
Matthieu DELINCE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hifibio Inc
Original Assignee
Hifibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hifibio Inc filed Critical Hifibio Inc
Publication of EP4367140A1 publication Critical patent/EP4367140A1/de
Publication of EP4367140A4 publication Critical patent/EP4367140A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP22837100.1A 2021-07-07 2022-07-06 Anti-tnfr2-antikörper und verwendungen davon Pending EP4367140A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163219175P 2021-07-07 2021-07-07
PCT/IB2022/000409 WO2023281313A1 (en) 2021-07-07 2022-07-06 Anti-tnfr2 antibody and uses thereof

Publications (2)

Publication Number Publication Date
EP4367140A1 EP4367140A1 (de) 2024-05-15
EP4367140A4 true EP4367140A4 (de) 2025-06-18

Family

ID=84800439

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22837100.1A Pending EP4367140A4 (de) 2021-07-07 2022-07-06 Anti-tnfr2-antikörper und verwendungen davon

Country Status (9)

Country Link
EP (1) EP4367140A4 (de)
JP (1) JP2024527576A (de)
KR (1) KR20240032985A (de)
CN (1) CN117980336A (de)
AR (1) AR126387A1 (de)
AU (1) AU2022308421A1 (de)
CA (1) CA3224693A1 (de)
TW (1) TW202309096A (de)
WO (1) WO2023281313A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023276940A1 (en) * 2022-05-26 2024-12-12 Pfizer Inc. Anti-tnfr2 antibodies and methods of use thereof
WO2024233258A1 (en) * 2023-05-05 2024-11-14 Cureimmune Therapeutics Inc. Anti-tnfr2 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061210A1 (en) * 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040312A1 (en) * 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3707163A4 (de) * 2017-11-09 2021-08-18 The General Hospital Corporation Antagonistische polypeptide der anti-tumor-nekrosefaktorrezeptorsuperfamilie
CN113874083A (zh) * 2019-03-01 2021-12-31 梅里麦克制药股份有限公司 抗-tnfr2抗体及其用途
US12297284B2 (en) * 2019-08-02 2025-05-13 Jiangsu Simcere Pharmaceutical Co., Ltd. Anti-TNFR2 antibody and use thereof
CA3154643A1 (en) * 2019-09-17 2021-03-25 Apexigen, Inc. Anti-tnfr2 antibodies and methods of use
CN112480259B (zh) * 2021-02-05 2021-05-04 百奥赛图(北京)医药科技股份有限公司 抗tnfr2抗体及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061210A1 (en) * 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2023281313A1 *
WEI SHUO ET AL: "DiscoveryandcharacterizationofnovelTNFR2antibodiestomodulateTcellactivities inimmunosuppressiveenvironment", AACR, vol. 80, 3 July 2020 (2020-07-03), pages 2282 - 2282, XP055913355, Retrieved from the Internet <URL:http://hifibio.com/wp-content/uploads/2020/07/Poster-2282-AACR-2020-conference-poster_TNFR2.pdf> [retrieved on 20250508], DOI: https://doi.org/10.1158/1538-7445.AM2020-2282 *

Also Published As

Publication number Publication date
CA3224693A1 (en) 2023-01-12
AR126387A1 (es) 2023-10-11
TW202309096A (zh) 2023-03-01
KR20240032985A (ko) 2024-03-12
EP4367140A1 (de) 2024-05-15
WO2023281313A1 (en) 2023-01-12
CN117980336A (zh) 2024-05-03
JP2024527576A (ja) 2024-07-25
AU2022308421A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
EP3838289A4 (de) Anti-tigit-antikörper und verwendungen davon
EP4388009A4 (de) Anti-ccr8-antikörper und verwendungen davon
EP3918323A4 (de) Anti-gal3-antikörper und verwendungen davon
EP4269435A4 (de) Anti-b7-h3-antikörper und verwendungen davon
EP3891183A4 (de) Anti-claudin-antikörper und verwendungen dafür
EP3762030A4 (de) Anti-cd73-antikörper und verwendungen davon
EP3759143A4 (de) Anti-tigit-antikörper und verwendungen davon
EP4100439A4 (de) Neuartige lilrb2-antikörper und verwendungen davon
EP4132974A4 (de) Anti-cd98-antikörper und verwendungen davon
EP3735427A4 (de) Anti-mct1-antikörper und verwendungen davon
EP4261223A4 (de) Anti-sirp? antikörper und anwendung davon
EP4281107A4 (de) Anti-kit-antikörper und verwendungen davon
EP4136116A4 (de) Anti-ox40-antikörper und verwendungen davon
EP3790586A4 (de) Anti-dll3-antikörper und verwendungen davon
EP3962954A4 (de) Anti-galectin-9-antikörper und verwendungen davon
EP3850012A4 (de) Anti-tnfrsf9-antikörper und verwendungen davon
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées
EP4010368A4 (de) Anti-nampt-antikörper und verwendungen davon
EP3755714A4 (de) Anti-angiopoietin-2-antikörper und verwendungen davon
EP4081548A4 (de) Anti-sirp? monoklonale antikörper und verwendung davon
EP3894440A4 (de) Anti-il-27-antikörper und verwendungen davon
EP3768317A4 (de) Anti-il-27-antikörper und verwendungen davon
MA55134A (fr) Anticorps anti-staphylococcus et leurs utilisations
EP3947462A4 (de) Anti-galectin-9-antikörper und verwendungen davon
EP4367140A4 (de) Anti-tnfr2-antikörper und verwendungen davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HIFIBIO, INC.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250520

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/39 20060101ALI20250514BHEP

Ipc: A61P 35/00 20060101ALI20250514BHEP

Ipc: C12N 15/13 20060101ALI20250514BHEP

Ipc: A61K 39/00 20060101ALI20250514BHEP

Ipc: C07K 16/28 20060101AFI20250514BHEP